|
|
Vaccine Detail
|
Western equine encephalomyelitis virus PE2/E1 mutant vaccine |
| Vaccine Information |
- Vaccine Name: Western equine encephalomyelitis virus PE2/E1 mutant vaccine
- Target Pathogen: Western equine encephalomyelitis virus
- Target Disease: Western equine encephalomyelitis (WEE)
- Product Name: WE2130
- Type: Live, attenuated vaccine
- Status: Research
- Host Species as Laboratory Animal Model: Chicken
- PE2
gene engineering:
- Type: Gene mutation
- Description: This PE2/E1 mutant is from Western equine encephalomyelitis virus (Turell et al., 2003).
- Detailed Gene Information: Click Here.
- E1
gene engineering:
- Type: Gene mutation
- Description: This PE2/E1 mutant is from Western equine encephalomyelitis virus (Turell et al., 2003).
- Detailed Gene Information: Click Here.
- Immunization Route: subcutaneous injection
|
| Host Response |
|
Chicken Response
- Persistence: WE2130 induced low-level viremia in chickens (Turell et al., 2003).
- Efficacy: WE2130 protected chickens from challenge with wild type WEE two weeks after initial vaccination (Turell et al., 2003).
|
| References |
Turell et al., 2003: Turell MJ, O'Guinn ML, Parker MD. Limited potential for mosquito transmission of genetically engineered, live-attenuated western equine encephalitis virus vaccine candidates. The American journal of tropical medicine and hygiene. 2003; 68(2); 218-221. [PubMed: 12641414].
|
|
